Single-chain variable fragment affinity tuning can optimize anti-AML CAR-NK cell functionality

Ruyan Rahnama1, Monika Kizerwetter2, Huilin Yang3

  • 1Oncology, Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA.

PubMed
Abstract

Insights

Chimeric antigen receptor (CAR)-NK cells targeting CD123 show potent anti-acute myeloid leukemia (AML) activity. Lower CAR binding affinity enhances NK cell discrimination of antigen density, leading to sustained antitumor effects in AML.

Area of Science:

  • Immunology
  • Cell Therapy
  • Oncology

Background:

  • Natural Killer (NK) cells possess inherent anticancer properties.
  • Chimeric antigen receptor (CAR) engineering redirects NK cell activity against cancer, including acute myeloid leukemia (AML).
  • The impact of CAR binding affinity and epitope targeting on CAR-NK cell function requires further investigation.

Purpose of the Study:

  • To investigate the functional consequences of varying CAR binding affinities and targeted epitopes on CAR-NK cell activation.
  • To analyze CAR-NK cell cytolytic synapse formation and antitumor efficacy against AML.
  • To understand how CAR affinity influences CAR-NK cell responses in different timeframes and models.

Main Methods:

  • Generated NK-92 and primary NK cells expressing AML-specific CARs (26292 or 7G3 targeting CD123) with variant affinities.
  • Conducted in vitro binding, activation, and cytotoxicity assays.
  • Utilized high-resolution imaging and mouse xenograft models for in vivo evaluation.

Main Results:

  • CARs were highly expressed and mediated antigen-specific activation.
  • High-affinity CAR-NK cells showed rapid AML cell killing, while low-affinity CAR-NK cells demonstrated superior antigen density discrimination and sustained cytotoxicity.
  • Low-affinity CAR-NK cells exhibited enhanced expansion in vivo.

Conclusions:

  • CAR-NK cell expression with varying CD123 binding affinities induces antigen-specific activation and cytotoxicity against AML.
  • Affinity-dependent functional differences are time-course and scFv/epitope specific.
  • Low-affinity CARs may offer advantages for sustained antitumor activity and in vivo expansion.